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Abstract
Background: Synaptojanin 2 Binding Protein (SYNJ2BP) is essential to cell proliferation. Previous studies show that
SYNJ2BP participates in sprouting angiogenesis, which plays an important part in several abnormal conditions
including cancer. However, the activity of SYNJ2BP in hepatocellular carcinoma (HCC) has not been elucidated yet.
Methods: Firstly, real-time PCR and western blotting (WB) were adopted to evaluate SYNJ2BP expressions in HCC
tissues and HCC cell lines. Secondly, we did follow-up and prognostic study to explore the association of SYNJ2BP
expression and HCC patients prognosis. Thirdly, we induced or silenced SYNJ2BP expression on selected HCC cell
lines and explored the function of SYNJ2BP in vitro and in vivo. Lastly, we conducted Cignal Finder Cancer 10-
Pathway Reporter Array in combination with loss- and gain-of-function assay to investigate potential mechanisms.
Results: Through various techniques we found that SYNJ2BP was decreased in HCC tissues and HCC cell lines. The
subsequent analysis showed that low expression of SYNJ2BP was associated with tumor size, tumor nodule
number, vascular invasion, TNM stage and BCLC stage, and was an independent risk factor for survival of HCC.
Later, the in vitro experiments demonstrated that SYNJ2BP inhibited HCC cells invasion, migration and proliferation,
also the in vivo testing revealed that SYNJ2BP inhibited tumor growth and metastasis. Finally, we also uncovered
that SYNJ2BP inhibited HCC growth and metastasis through activating DLL4-mediated Notch signaling pathway.
Conclusions: Collectively, our data provide evidence that SYNJ2BP may act as a tumor suppressor during HCC
development and could serve as a potential therapeutic target.
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Background
Hepatocellular carcinoma (HCC) is one of the most
common cancers worldwide and ranks as the second-
leading cause of cancer-induced death in men [1]. Espe-
cially for our country with a high incidence of hepatitis
B, the magnitude of the problem should never be under-
estimated [2]. With the development of modern medi-
cine, many technologies have been adopted in treatment
of HCC [3]. So far surgical resection is still the major strat-
egy for HCC, but the survival remains disappointing be-
cause of high rates of intrahepatic and extrahepatic
metastasis [4]. For that it seems reasonable to confirm
early detection and take timely treatment. Over the past
decades many molecular biomarkers involved in HCC
have been identified [5–8], and also researches on
microRNAs [9], lncRNA [10, 11] and inflammatory fac-
tors [12] have attracted extensive attention to scientists.
However molecular mechanisms of HCC development
are not fully understood, to further elucidate the mech-
anisms of HCC and explore effective treatment is of
paramount importance.
Synaptojanin 2 Binding Protein (SYNJ2BP) is a protein
(145 amino acids) coding gene located at 14q24.2 and can
regulate localization of Synaptojanin-2 and endocytosis of
Activin type II receptors [13, 14]. There have been
studies showing that SYNJ2BP protein has a single PDZ
domain and is widely expressed in vertebrates [13, 15].
Besides, Adam MG, etal. proved that SYNJ2BP stabilizes
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Notch ligands and inhibits sprouting angiogenesis [16].
Considering Notch signaling participates in vascular re-
modeling [17, 18] which plays an important part during
cancer progression [19, 20]. There’s been clear evidence
showing that Notch signaling goes hand in hand with
occurrence and development of many cancers [21, 22].
Existing studies also show that Notch signaling plays a
multifaceted role in cancer, and in some contex Notch
serves as a suppressor during HCC development [23, 24].
We also searched information with the aid of bioinformat-
ics, results from ‘The Cancer Genome Atlas’ (TCGA)
showed that a RNA-Seq screening containing 423 samples
showed that the relative expression of SYNJ2BP in HCC
tissues is obviously lower than that of peritumoral tissues
(PTs) (Supplementary), which is in accordance to our veri-
fication. Altogether, there are good reasons to hypothesize
that SYNJ2BP may play a role in HCC progression.
By far, there has been no research about SYNJ2BP func-
tion in HCC yet, so we conducted this study to explore
potential role of SYNJ2BP in HCC. First SYNJ2BP expres-
sion in human HCC tissues and cell lines were deter-
mined, and then SYNJ2BP function was tested in vitro
and in vivo. Finally, we investigated the potential molecu-
lar mechanisms of SYNJ2BP in HCC development.
Methods
Tissue specimens and patients
Patients and specimens in our study were derived from
the Second Xiangya Hospital of Central South University, we
selected 98 patients from 450 cases from January 2007 to
June 2010. All the patients received hepatectomy and no one
received neoadjuvant therapies. Among these patients, 28
matched fresh tumor tissues, peritumoral tissues (PTs) and 4
fresh normal live tissues (NLs) derived from hemangioma of
liver were selectively chosen. Tumor tissues were collected
from tumor nest, while PTs were obtained surrounding the
tumor tissues (1 cm from tumor margin). All the tissues
above were routinely snap-frozen in liquid nitrogen and
stored at 280 °C for real-time quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) and
western blot analysis. The samples employed for immunohis-
tochemistry (IHC) were paraffin embedded. Histopathology
was evaluated by two certified pathologists at the Depart-
ment of Pathology, the second Xiangya Hospital of Central
South University. In the part of observational study, written
informed consent was obtained from all patients before sur-
gery. All human materials were obtained with informed con-
cent from participants and approved by the Ethics Committee
of the Second Xiangya Hospital of Central South University.
RNA isolation, quantitative real-time reverse transcription
polymerase chain reaction (qRT-PCR)
Total RNA was extracted from cell lines or frozen tissues
using Trizol reagent (Invitrogen, Carlsbad, Calif) according
to the manufacturer’s protocol. Quantitative Real-time
PCR was performed using the SYBR Green Real-time
PCR Master Mix (Toyobo, Osaka, Japan) as described.
The primer sequences were as follows: for real‐time
PCR: SYNJ2BP forward, 5′-CTGCACCAGGATGCTG
TAGA-3′, SYNJ2BP reverse, 5′-TGGCACCAGCACCA
TAAATA-3′; GAPDH was used as an internal control
using the following primers: GAPDH forward, 5′-GCA
CCGTCAAGGCTGAGAAC-3′,GAPDH reverse, 5′-
TGGTGAAGACGCCAGTGGA-3′. All the primers
above were bought from Sangon Biotech.The experiments
were done in triplicates.
Western blotting
Total protein was extracted using RIPA lysis buffer supple-
mented with 1 % Phenylmethanesulfonyl (PMSF) and
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and then transferred onto
polyvinylidenefluoride (PVDF) membranes (Millipore,
Bedford, Mass). The blotted membranes were incubated
with appropriate antibody at optimal dilution. Finally, the
blots were developed using enhanced SuperSignal West
Pico chemiluminescence (Pierce Rockford USA). The
SYNJ2BP antibody was obtained from Proteintech group
(Proteintech, USA), corresponding secondary antibodies
and the other proteins were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).β-actin protein was also
determined by using the specific antibody (Santa Cruz,
CA) as a loading control. All experiments were carried
out in triplicates.
Immunohistochemistry
Formalin-fixed paraffin sections corresponding to previous
98 patients were gained, sections were stained for SYNJ2BP
using the streptavidin-peroxidase system (Zhong-shan
Goldenbridge Biotechnology, Beijing, China). Negative
control slides were probed with goat serum followed by
the secondary antibody under the same conditions. The
expression level of SYNJ2BP was scored using the
Shimizu [25] criteria. First scoring was obtained according
to percentage of positive hepatocytes: 0, ≤10 % positive;
1+, 11 % to 25 % positive; 2+, 26 % to 50 % positive; 3+,
51 % positive. Secondly, SYNJ2BP expression was scored
0, and 1+, 2+, and 3+ according to expression intensity.
Ultimately, we added the scores above, and SYNJ2BP
expression in HCC specimens was divided into a low-
expression group (0 or 1+) and a high-expression group
(2+ or 3+).
Follow-up and prognostic study
Our team conducted the follow-up part through tele-
phone or visiting regularly, recurrence or metastasis were
monitored by clinical examination, alpha-fetoprotein
levels, ultrasonography,high-resolution contrast-enhanced
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CT or magnetic resonance imaging (MRI) tests etc. Every
3 months in the first three years after operation and twice
a year after that are recommended. The follow-up began
the date of operation and ended the date of death or last
follow-up. Deaths from other causes were treated as cen-
sored cases. The period from hepatectomy to the signs of
recurrence was defined as disease-free survival (DFS).
Cell lines and cell culture
In this study, we adopted cell lines as follows: L02 (normal
liver cell line), Hep3B, HepG2, PLC/PRF/5, SMMC-7721
and HCCLM3 which are commonly used in HCC research.
Among the cells above: L02 cells were obtained from the
Tumor Institute of Central South University, Changsha,
China; Hep3B, HepG2, PLC/PRF/5, SMMC-7721 and
HCCLM3 cell lines were kindly gifted by the Shanghai
Institutes for Biological Sciences of the Chinese Acad-
emy of Sciences. All cells were maintained in Dulbecco’s
modified Eagle medium(GIBCO, Grand Island, NY)
supplemented with 10 % fetal bovine serum (GIBCO)
and 1 % antibiotics at 37°Cwith 5 % CO2.
Vector construction and transfection
According to SYNJ2BP expression profile, we chose
Hep3B and HCCLM3 cells for further investigation. All
the ectopic expression and knockdown lentiviruses as well
as their negative control (NC) lentiviruses were bought
from GeneChem (Shanghai,China). Then the plasmids
were transfected into corresponding cells. The ectopic
expression sequences for SYNJ2BP were: SYNJ2BP-for-
ward:5′-CCGCTCGAGATGGACTACAAAGACGAT
GACGACAAGAACGGAAGAGTG-3′, SYNJ2BP reverse:5′-
CGGGATCCTCAAAGTTGTTGCCGGTA-3′. The 3 can-







GGAGACATACTGC-3′.The NC sequences for SYNJ2BP
were: sense,5′-TTCTCCGAACGTGTCACGT-3′,antisense,
5′-ACGTGACACGTTCGGAGAA-3′. Finally, qRT-PCR
and Western Blot were carried out to validation the trans-
fection efficacy. All assays were carried out in triplicates.
Wound healing and transwell
One day before the wound healing assay, HCC cells were
seeded into 35 mm dishes. When cellular density reached
nearly 100 % confluence, we made a scraped line using a
small pipette tip, and then put the cells back to incubator.
In order to assess the rate of closure, micrographs were
taken every 24 hours using an inverted microscope IX51
(OLYMPUS) [26]. Transwell assay was used to assess cell
invasive ability [27]. A transwell dish has two chambers,
we added medium containing 10 % fetal bovine serum
(GIBCO) to the chamber below, while medium containing
0.1 % fetal bovine serum (GIBCO) to the upper chamber.
1 × 105 cells were seeded into the upper chamber pre-
coated with matrigel (BD Biosciences, Franklin Lakes, NJ)
and cultured at 37 °Cwith 5 % CO2. 48 hours later, we re-
moved gel and cells in the upper chamber and stained
cells below the membrane with crystal violet (Beyotime
Institute of Biotechnology). We managed to capture the
cells with inverted microscope (OLYMPUS, IX51, Japan)
and counted cells having got through the membrane. All
assays were carried out in triplicates.
MTT and colony formation
The MTT and colony formation assays were adopted to
assess cell proliferation ability. For MTT assay, after diges-
tion, 4000 cells together with 200 μl fresh medium were
seeded into each well of 96-well plates, wells merely con-
taining medium were used as negative control, and then
all plates were routinely put into incubator for seven days.
From the second day, we took six wells from each group
for detection every day. 100 μl fresh medium containing
MTT (5 mg/ml) was put into each well and incubated at
37 °C for 4 hours, then the medium was replaced by
150 μl DMSO and shaken at room temperature for
10mins. The absorbance was measured at 570 nm wave-
length [28]. For colony formation assays, 500cells together
with 2000 μl fresh medium were seeded into each well on
6-well plates (NEST Biotechnology Co.LTD.). Then cells
were incubated at 37 °C with 5 % CO2 atmosphere. Two
weeks later, medium was removed and cells were stained
with crystal violet (Beyotime Institute of Biotechnology,
Beijin, China) after washed. We captured the dishes with a
camera (Canon, EOS 760D, Japan) and counted colonies
which were bigger than 40um in diameter [29]. All assays
were carried out in triplicates.
Immunofluorescence
We also adopted immunofluorescence staining to analyze
SYNJ2BP influence on cell migration. The sterile coverslips
were laid on 6-well plates, each well with 1 × 105 cells, then
plates were incubated at 37 °C with 5 % CO2 atmosphere
overnight. The next day, Phalloidin (SIGMA, Louis MO,
USA) was used to stain F-actin filaments (red) of cells fixed
on coverslips; 4, 6-diamidino-2-phenylindole (DAPI) was
adopted to stain cell nuclei (blue). Then cell captures were
obtained with the aid of inverted microscope (OLYMPUS,
IX51, Japan). All assays were carried out in triplicates.
Cignal finder cancer 10-pathway reporter array
The Cignal Finder Cancer 10-Pathway Reporter Array
(Qiagen, Dusseldorf, Germany) was performed as de-
scribed to pinpoint pathways regulated by SYNJ2BP.
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After preparation of complex formation according to
the instruction, suspended cells were obtained from
exponential phase of growth cells (1 × 106/ml, 50 μl/
well). Then the 96-well plates were put at 37 °C with
5 % CO2 atmosphere, 6 hours later previous medium
was replaced with medium containing 10 % fetal bo-
vine serum without antibiotics. The next day,
complete medium were added and the cells were cul-
tured for another 48 hours. Finally, the luciferase
assay was carried out using the Dual-Luciferase Re-
porter Assay System (Promega, WI, USA).
HCC mouse model
According to experimental design, we established model
in BALC/c nude mice as described [30]. First we chose
4-week old male mice and randomly assigned them to
groups; and then 5 × 106 HCC cells were subcutaneously
injected to the left upper regions of nude mice respect-
ively; tumor diameter was measured using vernier calipers
every 3 days for 4 weeks. Four weeks later, tumors were
harvested and volume was calculated using the formula:
(Length ×Width2)/2 [30], meanwhile, tumors were also
cut into pieces(1.0 mm3).And then we implanted those
pieces under live capsule to mimic the primary HCC. Six
weeks later, we took the liver and lung of mice after
cervical dislocation and fixed the specimens with for-
maldehyde solution and embedded with paraffin. The
paraffin fixed tissues were serial sectioned and stained
with hematoxylin-eosin staining to identify metastastic
nodules. All animal studies met the National Institutes of
Fig. 1 Synaptojanin 2 Binding Protein (SYNJ2BP) is frequently down-regulated in hepatocellular carcinoma(HCC) tissues and HCC cell lines. a The SYNJ2BP
mRNA expression levels in 28 paired HCC tissues and peritumoral tissues (PTs) were obtained from quantitative real-time polymerase chain
reaction (qRT-PCR). Fold inductions were calculated using the formula 2-(△△Ct), GAPDH was used as internal control. The expression of
SYNJ2BP mRNA in PTs was used to normalize (value set to 1) the expression of SYNJ2BP mRNA in HCC tissues. b Western blot was also
adopted to validate SYNJ2BP expression levels in HCC tissues and PTs. The protein expression level of SYNJ2BP in HCC tissues was significantly lower
than that in PTs. *P < 0.05. But there were not significant differences between PTs and NLs (P = 0.442). c, d mRNA and protein expression levels of
SYNJ2BP were detected by qRT-PCR and western blot in one normal liver cell line (L02) and 5 HCC cell lines. The results showed that compared to L02
cells, Hep3B cells had the highest SYNJ2BP expression level, while HCCLM3 cells had the lowest expression level. Data were normalized to the
expression level of SYNJ2BP in L02. *P < 0.05. β-actin was used as the loading control
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Fig. 2 Immunohistochemistry of Synaptojanin 2 Binding Protein (SYNJ2BP) protein is down-regulated in HCC tissues and is closely related to patient
survival. Here shows representative images: a, b SYNJ2BP expression level is strongly high in PTs. c SYNJ2BP expression scored as 0. d SYNJ2BP
expression scored as 1+. e SYNJ2BP expression scored as 2+. f SYNJ2BP expression scored as 3+. Survival curves were calculated with the
Kaplan-Meier method, differences were evaluated using log-rank test. g According to IHC results, patients were divided into low expression group
(SYNJ2BP expression scored as 0 or 1+) and high expression group (SYNJ2BP expression scored as 2 or 3+). Results showed that HCC patients from the
low expression group had poorer OS (P = 0.001) and DFS (P = 0.006) than those from the high expression group. Original magnification: 400× for
(b); 100× for (a) and (c to f)
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Health guidelines and were approved by the Committee
on the Ethics of Animal Experiments of the Second
Xiangya Hospital of Central South University.
Statistical analysis
Statistical analysis was conducted using the statistical
software PASW Statistics version 18.0 (SPSS, Chicago, IL,
USA). We analyzed data for SYNJ2BP expression in fresh
specimens with Mann-Whitney U-test, adopted Fisher’s
exact test to analyze categorical data, and independent
t test for continuous data. Spearman rank-correlation
analysis was used to analyze the correlation between
SYNJ2BP expression and clinicopathological features. We
gained overall survival (OS) and disease-free survival
(DFS) curves using the Kaplan-Meier method, and com-
pared differences between the two groups by log-rank test.
Univariate and multivariate analysis was analyzed by Cox
proportional hazard regression model to verify the inde-
pendent risk factors. A two-tailed P value of less than 0.05
was considered as statistical significance. P values <0.05
was considered statistically significant.
Results
SYNJ2BP is down-regulated in human HCC tissues and HCC
cell lines
Our analysis showed that both SYNJ2BP mRNA and pro-
tein expressions were decreased in HCC tissues. Quantita-
tive real-time polymerase chain reaction (qRT-PCR) results
revealed that compared with peritumoral tissues (PTs),
mRNA expression of SYNJ2BP in HCC tissues were signifi-
cantly lower and the median fold-change was 0.23 (range,
0.01–1.28) (Fig. 1a). Similarly, western blot results showed
that the expression levels of SYNJ2BP protein in HCC
tissues were also significantly lower than that of PTs(0.31 ±
0.04 versus 0.83 ± 0.081; P < 0.01). In addition, the protein
expression difference between PTs and NLs was not statis-
tically significant (P > 0.05) (Fig. 1b). Meanwhile, the same
techniques above were also used to detect SYNJ2BP ex-
pression in L02 and HCC cell lines with different meta-
static potential [31]. The analysis showed that the mRNA
expression of SYNJ2BP in L02 cells was the highest
followed by Hep3B, the relative expression fold in Hep3B,
HepG2, PLC/PRF/5, SMMC7721 and HCCLM3 was 0.52,
0.28, 0.15, 0.03, and 0.01 respectively; we also found that
the protein expression levels of SYNJ2BP were the lowest
in HCCLM3 cells which owns strong metastatic ability,
the differences were statistically significant (Fig. 1c, d).
Low expression of SYNJ2BP in HCC tissues is associated
with poor clinicopathologic features of HCC
All the above findings suggested that SYNJ2BP probably
played a role in HCC suppressing, so we thought it ne-
cessary to do further exploration. Firstly we recruited
patients and their corresponding specimens mentioned
Table 1 Correlations between SYNJ2BP expression and
clinicopathological features of HCC
SYNJ2BP






Male 84 32 52
Female 14 7 7 0.399
Age (years)
≤ 60 71 28 43
> 60 27 11 16 0.906
Hepatitis B status
Negative 17 5 12
Positive 81 34 47 0.336
AFP(ng/ml)
<20 28 11 17
≥20 70 28 42 0.948
Liver cirrhosis
Presence 81 5 12
Absence 17 34 47 0.336
Tumor size (cm)
≤ 3 36 7 29
>3 62 32 30 0.002
Tumor nodule number
Single 47 7 40
Multiple (≥2) 51 32 19 <0.001
Vascular invasion
Presence 53 10 43
Absence 45 29 16 <0.001
Child-Pugh classification
A 76 31 45
B 22 8 14 0.709
TNM stage
I 40 8 32
II 9 2 7
III 49 29 20 <0.001
BCLC stage
0-A 54 9 45
B 9 4 5
C 35 26 9 0.001
Edmonson-Steiner grade
I-II 72 26 46
III-IV 26 13 13 0.215
Abbreviations: AFP alpha-fetoprotein, TNM tumor node metastasis, BCLC
Barcelona Clinic Liver Cancer
a Bold indicate statistical significance
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above and detected SYNJ2BP expression by immuno-
histochemistry (IHC). IHC results showed that SYNJ2BP
expression in HCC were significantly lower than that of
PTs (Fig. 2a to f). According to IHC results patients were
divided into SYNJ2BP high expression group (59 cases)
and low expression group (39 cases). Through Chi-square
Table 2 The Cox proportional hazard regression analyses for overall survival
Variables n Univariable Analysis Multivariable Analysis
HR (95% CI) P Value a HR (95% CI) P Value a
Gender
Male 14 1
Female 84 0.820(0.390-1.727) 0.602 n.a.
Age (years)
>60 27 1
≤60 71 0.815(0.456-1.456) 0.490 n.a.
Hepatitis B status
Negative 17 1
Positive 81 0.982(0.496-1.942) 0.958 n.a.
AFP(ng/ml)
≥20 70 1
<20 28 0.941(0.549-1.612) 0.824 n.a.
Liver cirrhosis
Absent 17 1
Present 81 0.606(0.329-1.118) 0.109 n.a.
Tumor size (cm)
≤3 36 1 1
> 3 62 2.998(1.714-5.244) <0.001 0.901(0.543-1.496) 0.687
Number of tumors
Single 47 1 1
Multiple (≥ 2) 51 2.772(1.632-4.707) <0.001 1.004(0.479-2.106) 0.991
Vascular invasion
Absent 45 1 1
Present 53 2.631(1.570-4.410) <0.001 1.758(1.313-2.353) <0.001
Child-Pugh classification
A 76 1
B 22 0.862(0.459-1.617) 0.643 n.a.
Edmondson-Steiner grade
I-II 72 1
III-IV 26 0.984(0.573-1.688) 0.952 n.a.
TNM stage
I/ II 49 1 1
III 49 2.003(1.490-2.692) <0.001 0.861(0.507-1.463) 0.580
BCLC
0-A 54 1 1
B/C 44 1.818(1.381-2.394) <0.001 2.118(1.177-3.814) 0.012
SYNJ2BP expression
Low 39 1 1
High 59 0.216(0.122-0.384) <0.001 0.279(0.125-0.620) 0.002
Abbreviations: AFP alpha-fetoprotein, TNM tumor node metastasis, BCLC Barcelona Clinic Liver Cancer, n.a. not adopted
a Bold indicate statistical significance
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test we found that SYNJ2BP low expression level was
significantly associated with large tumor size(P = 0.002),
multiple tumor nodules (P < 0.001), vascular invasion(P
< 0.001), high TNM stage(P < 0.001) and high BCLC
stage(P = 0.001) (Table 1), which belonged to poor
clinicopathological features of HCC. These results
Table 3 The Cox proportional hazard regression analysis for disease-free survival
Variables n Univariable Analysis Multivariable Analysis
HR (95% CI) P Value a HR (95% CI) P Value a
Gender
Male 14 1
Female 84 0.618(0.308-1.240) 0.176 n.a.
Age (years)
>60 27 1
≤60 71 0.589(0.342-1.011) 0.055 n.a.
Hepatitis B status
Negative 17 1
Positive 81 0.649(0.367-1.145) 0.135 n.a.
AFP(ng/ml)
≥20 70 1
<20 28 0.719(0.448-1.156) 0.173 n.a.
Liver cirrhosis
Absent 17 1
Present 81 0.662(0.369-1.188) 0.167 n.a.
Tumor size (cm)
≤3 36 1 1
> 3 62 1.901(1.175-3.074) 0.009 1.663(0.921-3.004) 0.092.
Number of tumors
Single 47 1 1
Multiple (≥ 2) 51 1.677 (1.059-2.656) 0.027 0.629(0.337-1.176) 0.147
Vascular invasion
Absent 45 1 1
Present 53 2.633(1.625-4.268) <0.001 2.023(1.679-2.998) 0.031
Child-Pugh classification
A 76 1
B 22 1.130 (0.640-1.993) 0.674 n.a.
Edmondson-Steiner grade
I-II 72 1
III-IV 26 1.138 (0.692-1.872) 0.611 n.a.
TNM stage
I/ II 49 1 1
III 49 1.882(1.440-2.461) <0.001 1.953(1.163-3.279) 0.011
BCLC
0-A 54 1 1
B/C 44 1.776(1.386-2.277) <0.001 0.941(0.589-1.503) 0.799
SYNJ2BP expression
Low 39 1 1
High 59 0.306(0.186-0.506) <0.001 0.461(0.230-0.927) 0.030
Abbreviations: AFP alpha-fetoprotein, TNM tumor node metastasis, BCLC Barcelona Clinic Liver Cancer, n.a. not adopted
a Bold indicate statistical significance
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indicated that SYNJ2BP expression was closely related
to biological behavior of HCC and could probably affect
the prognosis of HCC patients.
Low expression of SYNJ2BP in HCC tissues is associated
with poor HCC prognosis
In order to verify the association of low SYNJ2BP expres-
sion with poor clinicopathological features of HCC, we
went ahead to do clinical follow-up study on the same
patients. We analyzed the association between SYNJ2BP
expression level and prognosis. Survival curves revealed
that patients in the low expression group had shorter OS
and DFS than those in the other group. The 1-, 3- and 5-
year OS of patients with low SYNJ2BP expression were
62.2, 31.1 and 17.5 %; 78.6, 59.1 and 42.2 % for the pa-
tients in high SYNJ2BP expression group. The 1-, 3-, and
5-year DFS of patients in the low SYNJ2BP expression
group were 41.5, 18.1 and 6.6 %, which was significantly
lower than those in the other group (65.2, 39.9 and
22.8 %) (Fig. 2g).
In the meantime, we constructed Cox proportional haz-
ard regression model to see whether SYNJ2BP could serve
as an independent risk factors for HCC prognosis. Firstly,
through univariate and multivariate survival analysis,we
validated that SYNJ2BP expression level(P = 0.002) vascu-
lar invasion(P < 0.001) and BCLC(P = 0.012) stage were in-
dependent risk factors for overall survival(OS) (Table 2).
In addition, SYNJ2BP expression level (P = 0.030) vascular
invasion (P = 0.031) and TNM stage (P = 0.011) were also
considered to be independent risk factors for disease-free
survival (DFS) in the same cases (Table 3). As poor prog-
nosis of HCC is mainly due to tumor growth and metasta-
sis, we naturally associated SYNJ2BP with HCC metastasis
and growth.
SYNJ2BP inhibits HCC cells proliferation and migration
in vitro
To determine whether SYNJ2BP correlates with HCC me-
tastasis and growth, firstly we employed SYNJ2BP knock-
down and ectopic expression lentiviruses and their negative
Fig. 3 Hep3B cells were infected with SYNJ2BP lentivirus and control vector, HCCLM3 cells were also infected with shSYNJ2BP lentivirus and
control vector. a Western blot was performed to verify transfection efficacy. Results showed that the Sequence 1 is much more effective than
other two; and SYNJ2BP overexpression sequence increased expression level by more 90 %. Data were normalized to the expression level of
SYNJ2BP in untreated HCC cell. b Representative images showed that SYNJ2BP affected the cellular morphology of HCC cells. Cell nuclei were
stained with 4′,6-diamidino-2-phenylindole (blue). Original magnification: 400× for (b)
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control (NC) lentiviruses into Hep3B and HCCLM3 cell
lines respectively. Through western blot assessing, we
found that sequence 1 reduced the level of SYNJ2BP by
more than 90 %, and the overexpression sequence in-
creased SYNJ2BP expression level by more 90 %
(Fig. 3a). And then we used the above cell lines for sub-
sequent steps. In order to verify the above conjecture
we first carried out a series of in vitro studies. Methyl
thiazol tetrazolium (MTT) and colony formation assays
were performed to assess SYNJ2BP function in cell pro-
liferation (Fig. 4a, b). The results revealed that
HCCLM3 cells expressing SYNJ2BP showed a lower
proliferation rate and formed fewer colony numbers than
control cells. However, Hep3B cells expressing shSYNJ2BP
showed a higher proliferation rate and formed more col-
ony numbers than control cells.
Meanwhile, we adopted wound healing and transwell
assays to explore SYNJ2BP function in cell invasion
and migration (Fig. 4c, d). As shown in Fig. 4d,
Hep3BshSYNJ2BP and HCCLM3NC cells were more
hypermigratory. HCCLM3SYNJ2BP cells closed much
slower than that of HCCLM3NC cells (45 % versus
95 %, P <0.01); Hep3BshSYNJ2BP cells closed much fas-
ter than that of Hep3BNC cells. Meanwhile, the trans-
well assay showed that fewer HCCLM3SYNJ2BP cells
passed through the matrigel than that of HCCLM3NC
cells; more Hep3BshSYNJ2BP cells passed through the
matrigel than that of Hep3BNC cells. Additionally, we
also conducted immunostaining to examine morpho-
logic changes of cells. As shown in Fig. 3B, SYNJ2BP
suppressed stretch of F-actin, while knock down of
SYNJ2BP leaded to formation of stress fiber-like
structures, cell cytoskeletal and motility changes is
closely related to tumor metastasis [32]. All in all, it
is reasonable to presume that SYNJ2BP could inhibit
HCC metastasis and growth.
Fig. 4 Synaptojanin 2 Binding Protein (SYNJ2BP) inhibits proliferation, invasion and migration of hepatocellular carcinoma (HCC) cells. a MTT assay
was carried out to investigate proliferation ability in the above cells. Obvious increases of proliferation were observed in Hep3BshSYNJ2BP and HCCLM3NC
cells compared with Hep3BNC and HCCLM3SYNJ2BP cells respectively. (P < 0.05) b Colony formation assay was also conducted to measure proliferation
capacity of the above HCC cells. The results showed us that more colonies were formed in Hep3BshSYNJ2BP (192 ± 19) and HCCLM3NC (290 ± 28) cells as
compared with Hep3BNC (109 ± 21) and HCCLM3SYNJ2BP (160 ± 17) cells. (P < 0.05) c Transwell assay showed that more Hep3BshSYNJ2BP (81 ± 8) and
HCCLM3NC (103 ± 10)cells passed through the matrigel than Hep3BNC (23 ± 3) and HCCLM3SYNJ2BP (39 ± 2)cells. (P < 0.05) d For wound healing assay,
the results showed that the closure of Hep3BshSYNJ2BP (82 %) and HCCLM3NC (76 %) cells was significantly faster than that of Hep3BNC (31 %) and
HCCLM3SYNJ2BP (21 %) cells (P < 0.01). Original magnification: 200× for (c); 100× for (d); b pictures were captured by a camera. *P < 0.05
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SYNJ2BP suppresses HCC growth and metastasis in vivo
In the following research, we then developed HCC mouse
models using HCC cell lines to study SYNJ2BP on HCC
growth and metastasis. The results showed that SYNJ2BP
inhibited subcutaneous and orthotopic tumor size signifi-
cantly, as tumors originated from SYNJ2BP-transduced
HCCLM3 cells were dramatically smaller than their control
group; and tumor volume of the shSYNJ2BP group of
Hep3B cells was greater than the control group (Fig. 5a).
After harvest lungs were collected for Hematoxylin and eosin
(H&E) staining, as shown in Fig. 5b, we found that SYNJ2BP
overexpression groups contained fewer metastatic nodules
than those of the corresponding groups. Taken together, all
the above data supported that SYNJ2BP plays an important
part in suppression of HCC growth and metastasis.
SYNJ2BP exerts its function by activating DLL4 signaling
To investigate the mechanisms by which SYNJ2BP sup-
presses HCC growth and metastasis, we firstly adopted
the Cignal Finder Cancer 10-Pathway Reporter Array to
explore signaling pathways involved in this process. As
shown in Fig. 6a, in SYNJ2BP overexpression cells,
Notch signaling was stimulated and the activation degree
is significantly higher than that of control cell (3.79 ± 0.15,
P < 0.05). As Notch signaling is crucial to cell proliferation
and migration which shows good agreement with our pre-
liminary findings, so we thought it necessary to go on ex-
ploration tracing Notch signaling.
Previous studies have uncovered that SYNJ2BP could
stabilize DLL1 and DLL4-mediated Notching signaling in
endothelial cells which is particularly important for sprout-
ing angiogenesis [16]. Because also in endothelial cells,
DLL4 restrains angiogenic response triggered by vascular
endothelial growth factor (VEGF) [33]. We hypothesize that
SYNJ2BP sustains DLL4 to suppress tumor growth and
metastasis in human HCC. To test this hypothesis, we
detected expression levels of DLL1, DLL4 and VEGF in
Hep3BNC, Hep3BshSYNJ2BP, HCCLM3NC and HCCLM3SYNJ2BP
Fig. 5 Synaptojanin 2 Binding Protein (SYNJ2BP) inhibits HCC tumor growth and metastasis in vivo. The nude mice model was built using Hep3BNC,
Hep3BshSYNJ2BP, HCCLM3NC and HCCLM3SYNJ2BP cells. a Orthotopic tumor size in these two groups was calculated and compared. The size of tumors in
Hep3BNC and HCCLM3SYNJ2BP groups was significantly smaller than that of Hep3BshSYNJ2BP and HCCLM3NC groups respectively (P< 0.05). b Serial sections
of lung from model mice were stained with H&E to identify metastatic nodules, results showed that SYNJ2BP overexpression groups contained fewer(or
even none) metastasis nodules than those of their corresponding groups. Original magnification: 400× for (b); pictures from (a) were captured with the
aid of a canon camera
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cells. The results showed that knockdown of SYNJ2BP
decreased DLL4 expression level in HCC (Fig. 6b),
however, there’s no expression difference of DLL1 and
VEGF between Hep3BNCand Hep3BshSYNJ2BP cells. Op-
posite to Hep3B cells, overexpression of SYNJ2BP in
HCCLM3 cells elevated DLL4 expression but didn’t
affect DLL1 and VEGF. The results showed that DLL4
was positively related to SYNJ2BP, however, DLL1 and
VEGF had no correlation with SYNJ2BP.
SYNJ2BP stabilizes DLL4 level to suppress HCC growth
and metastasis
To confirm whether SYNJ2BP exerts its function by sus-
taining DLL4, we firstly induced or silenced DLL4 ex-
pression in previous HCC cells. The following loss- and
gain-of-function assay showed that overexpression of
DLL4 resembled SYNJ2BP-mediated proliferation and mi-
gration of HCC cells; conversely, silencing of DLL4 blocked
SYNJ2BP function (Fig. 7). Also, immunofluorescence (IF)
staining showed that cell morphology changed signifi-
cantly after transfection with DLL4 or short hairpin (sh)
DLL4. Upon DLL4 expression, cells displayed shrinkage of
F-actin; whereas knock down of DLL4 correlated with for-
mation of stress fiber-like structures(Fig. 6c). All these re-
sults suggest that SYNJ2BP suppresses tumor growth and
metastasis by targeting Notch signaling in hepatocellular
carcinoma. These results confirmed that restoration of
DLL4 could resemble SYNJ2BP in proliferation and mi-
gration of HCC cells, suggesting that SYNJ2BP suppresses
HCC growth and metastasis through DLL4 pathway.
Discussion
As one of the most common malignancies, HCC inci-
dence is still rising worldwide [1]. Although there have
been substantial advances in surgical and medical
treatment of HCC within past decades, the mortality
is remaining obstinately high [34]. Surveillance was
never cost-effective as the HCC incidence was high
Fig. 6 Synaptojanin 2 Binding Protein (SYNJ2BP) stimulates Notch signaling in hepatocellular carcinoma (HCC). Previous HCC cells transfected
with DLL4 expression or shDLL4 or control vectors were used in these studies. a Notch signaling was stimulated in cells overexpressing SYNJ2BP
while the other signaling pathways showed no significant change. b Western blot was employed to detect expression levels of DLL4, DLL1 and
VEGF, only DLL4 was positively related to SYNJ2BP. c Representative images showed that overexpression or silencing of DLL4 mimics or abrogates
SYNJ2BP mediated cellular morphology changes of HCC cells. Data were normalized to the expression level of SYNJ2BP in untreated HCC cell. Cell
nuclei were stained with 4, 6-diamidino-2-phenylindole (blue). Original magnification: 400× for C. *P < 0.05
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enough. It’s not difficult to see why as recurrence and
metastasis stand behind the situation above [35], and
even worse, mechanisms underlying HCC recurrence
still remain elusive. Through years of research work,
we placed more weight on illustrating mechanisms of
HCC metastasis and hope to develop effective thera-
peutic strategies to improve the quality of life for HCC
patients.
SYNJ2BP is a protein coding gene whose encoding
product is highly conserved in all eukaryotic species.
There have been studies demonstrating that SYNJ2BP
possesses a global role in regulating physiological pro-
cesses such as sprouting angiogenesis, stabilization or
localization of transmembrane proteins etc. [36] As
angiogenesis plays a part in cancer [19], and in the in-
stance of malignancy, HCC develops a neoplasm and
the formation of new vessels is required for its progres-
sion [37]. On the other hand, SYNJ2BP owns a PDZ
domain through which it interacts with ActRIIs to re-
duce activin to inhibit tumor growth [38–40]. So there
may be good reason to believe SYNJ2BP is essential to hu-
man HCC. However so far, the role of SYNJ2BP in human
HCC is completely unknown.
In this study, we adopted a series of techniques to val-
idate the role of SYNJ2BP in HCC metastasis and tried
to investigate the potential mechanisms. Firstly we mea-
sured SYNJ2BP expression in specimens by Real-time
PCR and western blot analysis, we found that both
SYNJ2BP mRNA and protein expression were signifi-
cantly lower in HCC tissues than that of corresponding
PTs. To confirm the findings above, we further detected
SYNJ2BP expression in HCC cell lines with different
invasion potential. Interestingly SYNJ2BP was down-
regulated in HCC cell lines and the expression level
was inversely proportional to high metastatic potential.
For the reason that SYNJ2BP was down-regulated in
Fig. 7 Overexpression or silencing of Delta-Like 4 (DLL4) imitates or counteracts Synaptojanin 2 Binding Protein (SYNJ2BP) mediated proliferation
and invasion of Hep3B and HCCLM3 cells. DLL4 expression or shDLL4 or control vectors were transfected into previous HCC cells. The MTT (a)
and colony formation analysis (b) were used to evaluate the proliferation abilities in Hep3B and HCCLM3 cells. The wound healing assay (c) and
transwell assay (d) showed the migration and invasion abilities of Hep3B and HCCLM3 cells. *P < 0.05. NC: Negative Control. Original magnification:
200× for C, 100× for D; pictures from B were captured with the aid of a canon camera
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HCC tissues and HCC cell lines, we naturally hypothe-
sized that up-regulation of SYNJ2BP might inhibit HCC
development and may act as a tumor suppressor. So sec-
ondly, we further explored whether SYNJ2BP expression
correlates with HCC prognosis. Through this study we
found that SYNJ2BP expression was significantly corre-
lated with poor clinicopathological characteristics of HCC.
We also proved that SYNJ2BP was associated with OS
and DFS in patients with HCC and could serve as an inde-
pendent risk factor. Accordingly SYNJ2BP highly likely
acts as a tumor suppressor in HCC development.
Next, we continued exploration of SYNJ2BP biological
function in vitro and in vivo. According to previous de-
tection, we employed shSYNJ2BP vector to knockdown
SYNJ2BP expression in Hep3B cell, and overexpression
vector to elevate SYNJ2BP expression in HCCLM3 cell.
Through a serial of approaches we found that ectopic
SYNJ2BP expression suppressed HCC cell proliferation
and metastasis potency, and down-regulation of SYNJ2BP
showed an opposite effect. The in vivo animal model
showed that overexpression of SYNJ2BP could inhibit
HCC growth and metastasis, while suppression of
SYNJ2BP showed opposite effects.
As Notch ligand, DLL4 is involved in angiogenesis,
endothelial cell proliferation and migration and angio-
genic sprouting ect [41]. And blockade of DLL4 causes
endothelial disruption. There have been studies showing
that in endothelial cells, SYNJ2BP could stabilize DLL1
and DLL4-mediated Notch signaling leading to poor
angiogenesis [16]. However, whether or not the same
mechanism exists in liver cells remains unknown yet. So,
we hypothesize that SYNJ2BP suppress HCC growth and
metastasis through stabilizing DLL4. To verify the above
hypothesis, firstly, the Cignal Finder Cancer 10-Pathway
Reporter Array was adopted to screen pathways involved,
interestingly, Notch signaling was indeed activated. So
next, we detected expressions of key proteins tracing
Notch signaling and VEGF, results showed that only DLL4
increased accompanying elevated expression of SYNJ2BP,
vise versa. Therefore, we introduced DLL4 or short
hairpin shDLL4 into above HCC cells and conducted
validation in vitro. The following loss- and gain-of-
function assay showed that overexpression of DLL4 re-
sembled SYNJ2BP-mediated proliferation and migration
of HCC cells; conversely, silencing of DLL4 blocked
SYNJ2BP function. Collectively, decreased expression of
SYNJ2BP in HCC likely contributes to HCC growth and
metastasis, partly through DLL4 pathway.
In conclusion, SYNJ2BP is decreased in HCC. We
confirm that SYNJ2BP indeed possesses the potency to
suppress HCC growth and metastasis through activating
DLL4 pathway. This study provides, for the first time,
evidence for a link between the biological activity of
SYNJ2BP and HCC growth and metastasis. That means
this great scientific finding, happily, unravels an unex-
pected function of SYNJ2BP that paves the way for early
detection of HCC recurrence.
Conclusion
Altogether, through in vitro and in vivo exploration, we
uncover SYNJ2BP suppresses HCC growth and metastasis.
The preliminary investigation showed that SYNJ2BP may
partly exert its function through inducing DLL4 signaling
pathway. However, the specific mechanism how SYNJ2BP
exerts its function in HCC still requires further study. We
believe with the development of modern technology there
will be new findings on the way investigating HCC.
For all we know, this is the first report to associate
the expression of SYNJ2BP with HCC. Our research in-
dicates that SYNJ2BP can be used as a potential marker
for HCC and may serve as a target for HCC treatment
in the near future.
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